Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Colorectal · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 2 · 50%High 0 · 0%

IRI with fluoropyrimidines vs single agent IRI

Overall survival (Death) · patients with advanced and/or metastatic colorectal cancer

IRI with fluoropyrimidines showed no clear difference in overall survival (Death) compared with single agent IRI (low certainty).

1 finding from 1 review

Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and… 2016 · Cochrane Headline outcomes only
HR 0.91 [0.81, 1.02]
5 studies · 1728 participants
Low

IRI with fluoropyrimidines vs single agent IRI

Progression‐free survival (PSF) · patients with advanced and/or metastatic colorectal cancer

IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).

1 finding from 1 review

Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and… 2016 · Cochrane Headline outcomes only
HR 0.68 [0.53, 0.83]
3 studies · 600 participants
Moderate

IRI with fluoropyrimidines vs single agent IRI

Grade 3/4 diarrhea · patients with advanced and/or metastatic colorectal cancer

IRI with fluoropyrimidines probably leads to lower grade 3/4 diarrhea compared with single agent IRI (moderate certainty).

1 finding from 1 review

Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and… 2016 · Cochrane Headline outcomes only
RR 0.66 [0.51, 0.85]
5 studies · 1179 participants
Moderate

IRI with fluoropyrimidines vs single agent IRI

Grade 3/4 nausea · patients with advanced and/or metastatic colorectal cancer

IRI with fluoropyrimidines showed no clear difference in grade 3/4 nausea compared with single agent IRI (low certainty).

1 finding from 1 review

Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and… 2016 · Cochrane Headline outcomes only
RR 0.33 [0.07, 1.58]
3 studies · 209 participants
Low